The University of the Free State (UFS) Department of Nuclear Medicine is proud to announce the successful treatment outcome of a patient with metastatic castrate-resistant prostate cancer (MCRPC) – an advanced stage of prostate cancer – by using Lutetium 177 PSMA (Lu-177 PSMA) therapy.
This was initially a case of advanced-stage prostate cancer, which had failed first-line chemotherapy, leaving little or no other treatment options. This is a proud and happy moment for the department and the UFS, which started this treatment over a year ago.
The university and the Free State province are now joining other South African medical universities, such as the University of Pretoria and other provinces, in using this method to treat MCRPC patients. Lutetium 177 PSMA (Lu-177 PSMA) therapy is used on MCRPC patients who are not eligible for chemotherapy or have failed first- or second-line chemotherapy.
Dr Gerrit Engelbrecht, Clinical Head of the Department of Nuclear Medicine at the UFS, says the department is proud to be able to offer this treatment option to some of these patients. “It is a big win for the Free State and our oncology patients to offer these expert services.”
The UFS and Universitas Academic Hospital have now joined other academic institutions and hospitals in other provinces to offer these services. So far, three patients have been offered this therapeutic option, with the third patient currently undergoing his treatment.
Funds and equipment for proper treatment selection are needed
The expertise is no longer an issue for the UFS, as Dr Osayande Evbuomwan, a nuclear medicine specialist and consultant, was trained and exposed to this therapy at the University of the Witwatersrand while training as a nuclear medicine resident.
Current registrars in the Department of Nuclear Medicine at the UFS are also being trained in applying this treatment modality. However, proper patient selection is key in managing these cases with Lu 177 PSMA. Without a PET/CT camera, it is challenging to appropriately select the patients who are most likely to respond to this therapy. This is an example of how PET/CT is crucial in managing and monitoring oncology patients.
Both Drs Engelbrecht and Evbuomwan hope that the training of more registrars will increase their department’s capacity to treat more patients. They also hope that funds will be made available to acquire a much-needed PET/CT camera, which will greatly assist them in identifying the correct patients in need of this treatment.
Treatment puts the department, UFS, and hospital on the map
According to Dr Evbuomwan, the ability to administer this treatment puts the department, the UFS, and the hospital on the map, alongside other top universities within and outside the country.
Says he: “It also creates an avenue for us to gather data for training, research purposes, and publications. We can now offer a promising, safe, and highly efficacious therapy for patients with MCRPC in the Free State. Some patients will no longer have to travel to other provinces to receive this treatment.”
“We are also well aware that not every patient will respond this way; however, proper patient selection is key in identifying responders – an area still being researched. We also do not know how long these patients will have their disease under control after the treatment. Nuclear medicine’s greatest cancer therapy success story is the treatment of well-differentiated thyroid cancer with radioactive iodine.”
“After treatment, most of these patients remain cancer-free for a very long period, if not for life. With continuing research in MCRPC radioligand therapy, we aim to improve the treatment modality, hopefully getting it to the success level of thyroid cancer therapy.”
Photo captions: The team of doctors in the Department of Nuclear Medicine behind the success story are, from the left (standing): Dr Osayande Evbuomwan, nuclear medicine specialist and Senior Lecturer; Dr Gerrit Engelbrecht, Clinical Head of the Department of Nuclear Medicine at the UFS; and Dr Walter Endres, nuclear medicine registrar. In front is Dr Tebatso Tebeila, nuclear medicine registrar. With the permission of the patient, the images above show the dramatic treatment response following Lu-177 PSMA therapy. The images on the left show widespread bone disease from the prostate cancer, including the skull. The images on the right show the dramatic response after completing four cycles of Lu 177 PSMA, with the normal excretion of the radiotracer seen in the liver, kidneys, and bladder.
